³Ìªñ¦U°ê¿n·¥µo®iªº¡uºë·ÇÂå¾Ç¡v¦³«Ü¦h¦n³B¡A¨ä¤¤³Ì¤jªº¦n³B¬O¥i¥H´î¤Ö¸ê·½®ö¶O¤ÎÁYµuªvÀø®É¶¡¡F¤×¨ä¬O«áªÌ¡A¹ïÀù¯g¯f±w¨Ó»¡·N¸q«¤j¡C¦]¬°Àù¯g¦³©Ò¿×ªº¶Àª÷ªvÀø´Á¡A¦pªG¥i¥H§Q¥Îºë·ÇÂå¾Ç¡A¦b¶EÂ_¥X¯f¤H¿©Àùªì´Á§Y¥i¥Hºë½T§PÂ_¯f¤H¾A¦X¨º¤@ºØªvÀø¤è¦¡¡An§ë¨º¤@ºØÃÄ¡A§Y¥i¥HÁקKµL®ÄªvÀø¡A´£¤ÉªvÀø®Ä²v¡C¹ï¬F©²¨Ó»¡¡AµL®ÄªvÀø®ö¶Oªº¬O°ê®a¸ê·½¡A¦ý¹ï¯f¤H¨Ó»¡¡AµL®ÄªvÀø®ö¶Oªº¬O¶Àª÷ªvÀø®É¶¡¡A¥i¯à·|³y¦¨µLªkÀ±¸Éªº¿ò¾Ñ¡C¼y©¯ªº¬O¡A¦p¤µÂǵۤj¼Æ¾Ú¤Î¤H¤u´¼¼z¡Aºë·ÇÂå¾Ç¤w¸gÂ÷§Ú̶V¨Ó¶Vªñ¡A¤]¶V¨Ó¶Vºë·Ç¡C¥[¤W¦U°ê¬F©²¿n·¥µo®i¡Aºë·ÇÂå¾Çªº´¶¤ÎÀ³¥Î¥i¥H»¡¬O«ü¤é¥i«Ý¡C
¦b9¤ë©³»P¥x¥_°ê»Úµo©úº[§Þ³N¥æ©ö®i¦P¨BÁ|¦æªº§Þ³N¥æ¬y½×¾Â¤¤¡A¸gÀÙ³¡¤u·~§½Á|¿ì¤F¤@³õ¡mÂåÀø¾¹§÷²£·~À³¥Î°Ó¾÷¡n¬ã°Q·|¡A¤À§OÁܽФF¤u¬ã°|¥ÍÂå»PÂå§÷¬ã¨s©Ò¡B¤u¬ã°|²£¸g¤¤¤ß (IEK) ¤Î ¥Íª«§Þ³N¶}µo¤¤¤ßªº±M®a¾ÇªÌ¨ÓºtÁ¿¡A±´°Q¤Fºë·ÇÂå¾ÇªºÂåÀø¾¹§÷µo®iÁͶաBµ¦²¤¡Bµo®i¼Ò¦¡¤Î°Ó¾÷µ¥µ¥¡C
ºë·ÇÂåÀø©w¸q¤Î¥Ø¼Ð
¤u¬ã°|²£¸g¤¤¤ß (IEK)¬ã¨sû½²©s¨k¦b¨ä¡uºë·ÇÂåÀø§Þ³N§G§½»P¥¼¨Óµo®i¡v³ø§i¤¤«ü¥X¡Aºë·ÇÂå¾Ç³Ì¦·½¦Û¬ü°ê¡A¦¦b2011¦~¬ü°ê°ê®a¬ã¨s©eû·| (United States National Research Council)¤w ´£¥X¦¹¤@·§©À¡Fª½¨ì¬ü°êÁ`²Î¼Ú¤Ú°¨©ó2015¦~°ê±¡«t¤å¤¤´£¥X ¡uºë·ÇÂå¾Çpµe¡v ¡]Precision Medicine Initiative¡APMI¡^ ¡A§Y¶}©l¼s¨ü¥þ²yÆf¥Ø»P°Q½×¡C
ºë·ÇÂå¾Ç¦bPMI¦³©ú½Tªº©w¸q¡A«üªº¬O¡u°ò©óÓÅ鶡°ò¦]®t²§©Ê¡BªÀ·|Àô¹Ò©M¥Í¬¡«¬ºAµ¥¤£¦P¡A´£¨Ñ³Ì¾A¦Xªº¹w¨¾»PªvÀø±¹¬I¡v(An emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.)¡CµM¦Ó¡AÁöµM¬O°w¹ïÓÅ鶡ªº®t²§¨Ó´£¨Ñ¾A¦XªºªvÀø±¹¬I¡A¦ý¸òÓ¤H¤ÆÂåÀø¬O¤£¤@¼Ëªº¡Cºë·ÇÂåÀø¨Ã¥¼¹ï¨C¤@¦ì±wªÌ¥Í²£¿W¯SªºÃĪ«©ÎÂåÀø³]³Æ¡A¦Ó¬O®Ú¾Ú±wªÌªº¯S©w¯e¯f©ö·P©Ê¡B©Ò±w¯e¯f¥Íª«¾Ç°ò¦¡A¥H¤Î¹ï¬YºØ¯S©wªvÀøªº¤ÏÀ³®t²§¡A±N±wªÌ¤À¬°¤£¦P¨È¸s¡]Subsets¡^¡A´£«ý¨CӨȸsªº¯S©w¯e¯fªºÀøªk¡A´£¤ÉªvÀø¦³®Ä©Ê¡A°§CÂåÀø¤ä¥X¡C
¥HÀù¯g¬°¨Ò¡A¤w¸g¦³³\¦h¬ã¨sÃÒ¹êÀù¯g¬O¤@ºØ°ò¦]Åܲ§ªº¯e¯f¡C°ò¦]Åܲ§ªºµo¥Í¥Dn¦³¨âºØ¨Ó·½¡A¤@ºØ¬O»P¥ÍѨӪº¥ý¤Ñ°ò¦]¿ò¶Ç¡A¥Dn©M®a±Ú¿ò¶Ç¦³Ãö¡A¥t¥~¤@ºØ¸g¥ÑÀô¹Ò©M¥Í¬¡²ßºDªø´Á±µÄ²PÀùª«½è¡A³y¦¨·sªº°ò¦]¬ðÅܲ£¥Í¡AÅý¤@¨ÇÃöÁ䪺°ò¦]¥¢¥hÀ³¦³ªº¥\¯à¡A³y¦¨Å餺²ÓMªº¹B§@¥¢¿Å¡B¥¢±±¡A¶i¦ÓÅý²ÓMµo¥ÍÀù¤Æ¯fÅÜ¡A²£¥ÍÀù²ÓM¦bÅ餺§Ö³t¥ÍªøÂX´²¡C¦b³oºØ±¡ªp¤U¡Aºë·ÇÂåÀø¤£¬O°w¹ïÓ§O¯f±w´£¨Ñ¿W¯SªºÃĪ«¡A¦Ó¬O±N¤@¤j¸sÀù¯g¯f±w´N¨ä¹ï¯S©wÂåÀøªº¤ÏÀ³®t²§¨Ó¤À¦¨¤£¦Pªº¤p²Õ (¨È¸s)¡A¦b³oºØ±¡ªp¤U¡A¥un°w¹ï¨È¸s¯S©Ê§@¬ã¨s§Y¥i¡A´£«ý¨CӨȸsªº¯S©w¯e¯fªºÀøªk¡A¥ÎÃĺë·Ç«×¥i¤j¬°´£¤É¡C
¦b¥H«e¨S¦³ºë·ÇÂåÀøªº±¡ªp¤U¡A¸I¨ìÀù¯g¯f±w³£¬O¥Î¡u¸Õ¡vªº¡G¥ý¸Õ¤@¸Õ¤ÆÀø¡A¤£¦æ¦A´«¼Ð¹vÃĬݬݡA¦pªG³oºØ¼Ð¹v¨S®Ä¦A´«¥t¥~¤@ºØ¡K¡K¦b³oºØ±¡ªp¤U¡A°£¤FÂåÀø¸ê·½®ö¶O¥~¡A¯f±wªº¶Àª÷ªvÀø®É¶¡¤]¬O¤@ÂI¤@ºwªº¬y¥¢¡C¤Ï¤§¡A¦bºë·ÇÂåÀø±¡ªp¤U¡A·|¥ý´N¯f±w°ò¦]¯S©Ê±N¨äÂkÃþ¨ì¯S©w¨È¸s¡AµM«á¦A´N¨È¸s¯S©Ê§ëÃÄ¡A¦p¦¹¤@¨Ó¡A¦³®Ä²v§Y·|´£¤É¡C
½²©s¨k«ü¥X¡Aºë·ÇÂå¾Çªºµu´Á¥Ø¼Ð¬O¥Î©óÀù¯gªvÀø¡A§Æ±æ¥i¥H°w¹ïÀù¯g¯f¤Hºë·Ç¥ÎÃÄ¡F¦Óªø´Á¥Ø¼Ð«h¬O´N¤HÃþ°ò¦]¸ê®Æ®w¤ÀªRÀ³¥Î¡A´£¨Ñ°·±dºÞ²zªA°È¡C
ªvÀøÆ[©À§ïÅÜ¡@ÃĪ«¤£¦A¤@Åé¾A¥Î
ºë·ÇÂåÀø¤§©Ò¥H¯à¹F¦¨¡A¦³«Ü¤j³¡¤À¬O¾a¸ê®Æ·j¶°¤Î¸ÑŪ¡A³o¨Ç¸ê®Æ³Ì¥Dn¬O°ò¦]¸ê®Æ¤ÎÓÅé®t²§¡]¦p¥Í¬¡¡B¶¼¹²ß©Êµ¥¡^¡C¦p¹Ï¢°©Ò¥Ü¡A·í¸ê®Æ·j¶°¨ì»Ý¨Dªº¶qªº®ÉÔ¡A§Y¥i¶i¦æ¤À¸s¡]ªvÀø¡^¡A¦A°w¹ï¤£¦P¤À¸s§@¼Æ¾Ú¤ÀªR¤Î¬ã¨s¡AµM«á±N¤ÀªR©Ò±o¸ê®ÆÂk¯Ç¾ã²z¦¨¨t²Î¤Æ¤§¦³¥Î¸ê°T¡]¹Ï1¥kÃ䤧°Ï¶ô¡^¡A³o¨Ç¸ê°T§Y¥i§@¬°ºë·Ç¥ÎÃĤ§°Ñ¦Ò¨Ì¾Ú¡C
¹Ï2.¦U¥Dn¯e¯f§ëÃĵL®Äªº¤ñ¨Ò | ¤u¬ã°|²£¸g¤¤¤ß (IEK)¬ã¨sû½²©s¨k |
| |
¹Ï2¬O¦U¥Dn¯e¯f§ëÃĵL®Äªº¤ñ¨Ò¡]2001¦~¬ã¨s¼Æ¾Ú¡^¡A¨ä¤¤Àù¯gÃĪ«§ëÃĵL®Ä¤ñ¨Ò³Ì°ª¡A¹F75%¡C
½²©s¨k«ü¥X¡A³o¥Dn¬O¥Ñ©ó¦b¶Ç²ÎªvÀø¹Lµ{¤¤¡A¦³¨Ç±Ú¸s¹ïÃĪ«¤ÏÀ³¤£¨Î¡A¬Æ¦Ü¦³ÄY«°Æ§@¥Î¡A¸Ñ¨M¤èªk¬O¥H¬ÛÃö¥Íª«¼Ð»x (Biomarker) ¿ë§O¾A¦X¸ÓÃĪ«ªº±Ú¸s¡A¥H§óºë·ÇªºªvÀø¡A¹F¨ì´î¤ÖÃÄ«~°Æ§@¥Î²£¥Í¥H¤ÎÂåÀø¸ê·½®ö¶Oªº¥Øªº¡C
½²©s¨kªí¥Ü¡A®Ú¾Ú2002¦~¤@¶µ¬ã¨s«ü¥X¡A¦b¥H¼Ð¹vÃĪ«Trastuzumab (¼Ð¹v°ò¦]HER2)§@¬°¤@½uªvÀø®É¡Aµo²{¸g¹L¥HFluorescence in situ Hybridization (FISH) ÀË´úHER2¤À¸s¹Lªº¯f±w¤¤¡A¹ïÃĪ«¦³¤ÏÀ³ªº¯f±w±q7%´£¤É¦Ü34%¡FÅã¥Ü°ò¦]ÀË´ú¤À¸s¥iºë·Ç¥ÎÃĨùw´úÀø®Ä¡C
¥t¤@¶µ«nªºÀù¯g«D¤p²ÓMªÍÀù (NSCLC)¡Aì¥ýÁ{§É¸ÕÅçµo²{¤ÆÀøµL®ÄªºNSCLC¯f±w¦b¸g¹LEGFR¿z¿ï«á¡A¨Ï¥Îanti-EGFR¤p¤À¤lÃĪ«ªvÀø¤ÏÀ³¥i¹F10-20%¡A¨Ï±o³o¨ÇÃĪ«³q¹L¤W¥«¼f¬d¡C½²©s¨k«ü¥X¡Aªñ´Áªº¬ã¨sµo²{³o¸s¯f±w¤¤´ÁEGFR±a¦³¬ðÅÜ¡A¨Ï±o¹ïTyrosine Kinase Inhibitor (TKI) ÃþÃĪ«±Ó·P¡A¦]¦¹¡A¦pªG¥i¥H¹w¥ý¿z¿ï³oÃþ¯f±w¡A§Y¥i±NªvÀø¤ÏÀ³²v´£¤É¦Ü50%¥H¤W¡A¨Ã©µ¯f±wªø¦s¬¡®É¶¡¡C
¥Ñ¦¹¥i¨£¡Aºë·ÇÂåÀø¤£¶È¹ï¯f±w¨Ó»¡¬OºÖµ¡A¹ï©ó§ë¤J·sÃĬãµoªºÃļt¦Ó¨¥¡A¤]¬O¬Û·í«nªº¡C
¥@¬É¦U¤j°êºë·ÇÂåÀø²£·~µo®i±¡ªp
¬ü°ê
¹wp¶Ò¶°100¸U¤Hªº°ò¦]¸ê®Æ¡A³z¹L¬ã¨s¤£¦P±Ú¸s¡B¦UÓ¦~ÄÖ¼hªºÓ¤H¤Æ°ò¦]¸ê°T¡A¨Ó¨ó§UªvÀøÀù¯g»P¿}§¿¯fµ¥¯e¯f¡B¥H¤Î¬ã¨s¿ò¶Ç©ÊÅܲ§¹ï¤HÅé°·±d©M¯e¯f§Î¦¨©Ò²£¥Íªº¼vÅT¡C«áÄò·|«Ø¥ß°_§¹¾ãªº°ò¦]¸ê®Æ®w¡A¥H¼Ð·Ç¤Æ¨BÆJ¹ê¦æºë·ÇÂåÀø¡C¥Ñ©ó³oÄݩ󤽦@°]¡A¦]¦¹»Ýn¥Ñ¬F©²¨Ó¶i¦æ¡C
- µu´Á¥Ø¼Ð¡G¥Dn°w¹ïÀù¯gªvÀø¡A¥]§t¼Ð¹vÃĪ«ªºÁ{§É¸ÕÅç¡B¾ã¦XÀøªk (combination therapy) ¥H¤Î§ÜÃĩʪº¬ã¨s¡A¨Ã±Ò°ÊNCI-MATCHpµe¡C
- ªø´Á¥Ø¼Ð¡G§¹¦¨100¸U¤H¦¸ªº¥Íª«¸ê®Æ®w¡A¥[±jÃĪ«°ò¦]Åé¾Ç¡BÓ¤H°·±dºÞ²z»P¿Ô¸ß¡A¥H¤Î§ó¦h°ò¦]¯e¯f¡B±Ó·P©Ê¯e¯f¡BºC©Ê¯e¯fªº¹w¨¾©MªvÀø¡C
^°ê
^°ê¬F©²©ó2013¦~«Å¥¬±Ò°Ê¬°´Á4¦~ªº¡u10¸U°ò¦]Åépµe¡v¡A2015¦~°l¥[3.75»õ¬ü¤¸§ë¤J°ò¦]¸ê®Æ®wªº«Ø¥ß¡A¨Ã©ó2016¦~6¤ë§¹¦¨9,892Ó°ò¦]²Õ©w§Ç¡C
2014¦~4¤ë^°ê°ê®a³Ð·s§½ (Innovate UK) ³]¥ßºë·ÇÂåÀø±À¶i¾¹¡A¥[³tºë·ÇÀË´ú©MÓÅé¤Æ¥ÎÃĪºµo®i¡A¨Ã¹wp2015¦Ü2021¦~§ë¤J93»õ¬ü¤¸¡C°ê®a³Ð·s§½¬°ºë·ÇÂåÀø±À¶i¾¹«e5¦~ªº¹BÀç¼·´Ú7,760¸U¬ü¤¸¡AµÛ¤â¸Ñ¨Mºë·ÇÂåÀø²£«~ªº²~ÀV°ÝÃD¡A¨Ò¦p°Ó·~¼Ò¦¡¡BÁ{§É¸ÕÅç¡B¸ê°TªA°È¾ã¦X»P¨Ñµ¹µ¥¡C
2015¦~10¤ë26¤é«Å¥¬¦¨¥ß6Óºë·ÇÂåÀø¨ô¶V¤¤¤ß¡A«Ø¥ß°ê®aºë·ÇÂåÀøºôµ¸¡C½²©s¨k«ü¥X¡A¥Ñ©ó^°êªºÂåÀø¨î«×¬O¤½¯q¨î¡AÂå¥Í³£¬O¤½°Èû¡A©Ò¦³Âå°|³£¬O¤½¥ßÂå°|¡A¦Ó¤½¥ßÂå°|¦³«Ü¤jªº¸ê®Æ®w¥i¥Î¡A¨Ã¥B¥i¥H§Î¦¨ºu°Ê¦¡¸ê®Æ®w¡A¸ê®Æ®w¤º®e¥i¤£Â_§ó·s¡C
¤¤°ê¤j³°
2015¦~1¤ë½Ãp©eµo¥¬¤F¡mÃö©ó¶}®i°ª³q¶q°ò¦]´ú§Ç§Þ³NÁ{§ÉÀ³¥Î¸ÕÂI³æ¦ì¥Ó³ø¤u§@ªº³qª¾¡n¡A¨Ã³°Äò³q¹L20®aÂåÀø¾÷ºc»P¥Á¶¡¥ø·~¥Ó½Ð¡A¤ñ·~¬É¹w´Án¦h¡AÅã¥Ü¤¤°ê¤j³°ªº¿n·¥¥¬§½¡C
©ó2015¦~3¤ë©ÒÁ|¦æªº¡uºë·ÇÂåÀø¾Ô²¤±M®a·|ij¡v¨î©w¤Fºë·ÇÂåÀøµo®i¤è¦V¡A¥H¥þ¹Lµ{¡B¥þn¯À¡B¥þ§½©Êªº¹ïÂåÀø¹Lµ{©MÁ{§ÉªvÀø¶i¦æÀu¤Æ¡C¬F©²p¹º©ó2030¦~«e¡A§ë¤J600»õ¤H¥Á¹ôµo®iºë·ÇÂåÀø¡A¨ä¤¤200»õ¤H¥Á¹ô¥Ñ¤¤¥¡°]¬F¤ä¥I¡A400»õ¥Ñ¥ø·~©M¦a¤è°]¬F°t¦X¡C
2015¦~3¤ë¥Ñ¥_¨Ê¨ó©MÂå°|¡B¥|¤t¤j¾ÇµØ¦èÂå°|®i¶}100¸U¤H°ò¦]¸ê®Æ®w«Ø¸m¡C
2015¦~7¤ë¡A½Ãp©eÂå¬FÂåºÞ¥q¡Aµo¥¬¤F¡m¸~½FÓÅé¤ÆªvÀøÀË´ú§Þ³N«ü«n¡n¡B¡mÃĪ«¥NÁ–¡©MÃĪ«§@¥Î¹vÂI°ò¦]ÀË´ú§Þ³N«ü«n¡nµ¥ºë·ÇÂåÀø»â°ì¤§µo®i³W½d¡C¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n196´Á¡GÀù¯g¯f¤HªººÖµ¡G¤j¼Æ¾Ú¡Ï¤H¤u´¼¼zÅýºë·ÇÂåÀø³v¨B¹ê²{¡j
¥_¬ü´¼ÅvPVIGO¡u±M§Q¦~¶O¥Nú±M°Ï¡v§Y¤é°_¬°±z§Ö³tªA°È¡I